Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20501830
Miyazawa Y, et al. (2010) CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Res 70, 5136-46 20501830
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y734-p - CDCP1 (human)
Modsite: KDNDsHVyAVIEDTM SwissProt Entrez-Gene
Orthologous residues
CDCP1 (human): Y734‑p, CDCP1 (mouse): Y731‑p, CDCP1 (rat): Y731‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Disease tissue studied:  gastric cancer, gastric carcinoma, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  BxPC-3 (pancreatic), Capan1 (pancreatic), CFPAC-1 (pancreatic), HSC44As3 (gastric), HSC59 (gastric), PANC-1 (pancreatic), Suit4 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  human
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Effect of modification (process):  cell motility, altered
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
PKCD (human) Induces enzymatic activity, induced, phosphorylation, molecular association, regulation cell motility, altered microscopy-colocalization, co-immunoprecipitation
Comments:  regulates migration, invasion, and extracellular matrix degradation

Y313-p - PKCD (human)
Modsite: ssEPVGIyQGFEKkT SwissProt Entrez-Gene
Orthologous residues
PKCD (human): Y313‑p, PKCD iso2 (human): Y313‑p, PKCD (mouse): Y311‑p, PKCD iso2 (mouse): Y311‑p, PKCD (rat): Y311‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  BxPC-3 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
phorbol_ester CDCP1 (human) augment treatment-induced increase CDCP1 siRNA inhibits

T507-p - PKCD (human)
Modsite: FGEsRAstFCGtPDy SwissProt Entrez-Gene
Orthologous residues
PKCD (human): T507‑p, PKCD iso2 (human): T538‑p, PKCD (mouse): T505‑p, PKCD iso2 (mouse): T531‑p, PKCD (rat): T505‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  BxPC-3 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol_ester increase
CDCP1 (human) no change compared to control CDCP1 siRNA no change